Why Kenvue Stock Is Down in Premarket Today: Trump Team Targets Tylenol–Autism Link
-
最新报道：Kenvue Inc. (NYSE: KVUE) shares dropped 6.05% to $17.24 in premarket trading following reports that the Trump administration plans to announce a potential link between Tylenol use during pregnancy and autism risk. Health officials are expected to caution against early-pregnancy Tylenol use unless for fever treatment, while promoting leucovorin as a potential autism therapy. The announcement, championed by Health Secretary Robert F. Kennedy Jr., has intensified scrutiny over Kenvue's flagship product, which has already faced a 15% stock decline this month amid safety concerns.
下一篇
MBX Biosciences Stock Skyrockets After Announcing Significant Phase 2 Results
- MBX Biosciences (NASDAQ: MBX) shares surged 139.10% to $23.91 in premarket trading after i...
24小时热点
热点专题
415697